Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Therapeutic Targeting Of Replicative Immortality, Paul Yaswen, Karen L. Mackenzie, W. Nicol Keith, Patricia Hentosh, Francis Rodier, Jiyue Zhu, Gary L. Firestone, Ander Matheu, Amancio Carnero, Alan Bilsland
Therapeutic Targeting Of Replicative Immortality, Paul Yaswen, Karen L. Mackenzie, W. Nicol Keith, Patricia Hentosh, Francis Rodier, Jiyue Zhu, Gary L. Firestone, Ander Matheu, Amancio Carnero, Alan Bilsland
Medical Diagnostics & Translational Sciences Faculty Publications
One of the hallmarks of malignant cell populations is the ability to undergo continuous proliferation. This property allows clonal lineages to acquire sequential aberrations that can fuel increasingly autonomous growth, invasiveness, and therapeutic resistance. Innate cellular mechanisms have evolved to regulate replicative potential as a hedge against malignant progression. When activated in the absence of normal terminal differentiation cues, these mechanisms can result in a state of persistent cytostasis. This state, termed “senescence,” can be triggered by intrinsic cellular processes such as telomere dysfunction and oncogene expression, and by exogenous factors such as DNA damaging agents or oxidative environments. Despite …
Designing A Broad-Spectrum Integrative Approach For Cancer Prevention And Treatment, Keith I. Block, Charlotte Gyllenhaal, Leroy Lowe, Amedeo Amedei, A.R.M. Ruhul Amin, Amr Amin, Katia Aquilano, Jack Arbiser, Alexandra Arreola, Alla Arzumanyan, Patricia Hentosh
Designing A Broad-Spectrum Integrative Approach For Cancer Prevention And Treatment, Keith I. Block, Charlotte Gyllenhaal, Leroy Lowe, Amedeo Amedei, A.R.M. Ruhul Amin, Amr Amin, Katia Aquilano, Jack Arbiser, Alexandra Arreola, Alla Arzumanyan, Patricia Hentosh
Medical Diagnostics & Translational Sciences Faculty Publications
Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity “broad-spectrum” therapeutic …